Una vacuna experimental de ARNm muestra protección contra múltiples virus del Ébola

Una vacuna experimental de ARNm ha demostrado eficacia contra tres cepas del virus del Ébola en pruebas con roedores. La vacuna se dirige a los virus Zaire, Sudán y Bundibugyo. Los investigadores la desarrollaron en medio de un brote continuo del virus Bundibugyo en África.

Yanfeng Yao y sus colegas del Instituto de Virología de Wuhan crearon la vacuna combinando secuencias de ARNm para las glicoproteínas de cada virus junto con una nucleoproteína compartida dentro de una nanopartícula lipídica. En las pruebas, los ratones inmunizados obtuvieron protección completa contra los virus Zaire y Sudán, y una fuerte protección contra el Bundibugyo. Los hámsteres también recibieron protección total tras la exposición al virus Sudán.

Artículos relacionados

Photorealistic lab scene depicting DoriVac DNA origami vaccine triggering strong immune responses in mouse and organ chip models, as an advance over mRNA vaccines.
Imagen generada por IA

DNA origami “DoriVac” shows strong immune activation in early tests, offering a potential complement to mRNA vaccines

Reportado por IA Imagen generada por IA Verificado por hechos

Researchers at Harvard’s Wyss Institute and Dana-Farber Cancer Institute report that a DNA origami-based vaccine platform called DoriVac generated robust immune responses in mice and in a human lymph node “Organ Chip” model. The team says the approach could be easier to store and manufacture than lipid nanoparticle–delivered mRNA vaccines, though the work remains preclinical. The results were published in Nature Biomedical Engineering.

Moderna confirmed ongoing work on an mRNA vaccine for hantavirus following a deadly outbreak on a Dutch cruise ship. The effort, in partnership with Korea University, began in 2023 and shows promise but remains years from completion.

Reportado por IA

The World Health Organization has declared a public health emergency over an outbreak of the Bundibugyo strain of Ebola virus in the Democratic Republic of the Congo and Uganda. The move comes as researchers urge faster development of vaccines for lesser-known Ebola strains.

TBE cases in Sweden have tripled over ten years despite rising vaccinations. Åke Lundkvist, professor of virology at Uppsala University, suspects the virus may have changed, reducing vaccine effectiveness. Researchers are now analyzing 12,000 ticks to investigate.

Reportado por IA

Egypt's Ministry of Health aims to produce 140 million human vaccine doses annually by 2030 under its Vaccine City project. Health Minister Khaled Abdel Ghaffar reviewed the project's progress, emphasizing efforts for self-sufficiency and exports to regional and international markets.

Este sitio web utiliza cookies

Utilizamos cookies para análisis con el fin de mejorar nuestro sitio. Lee nuestra política de privacidad para más información.
Rechazar